课题基金 / 基金详情

RAP as a novel therapeutic to promote remyelination after MS demyelinating event

RAP as a novel therapeutic to promote remyelination after MS demyelinating event
RAP 作为促进 MS 脱髓鞘事件后髓鞘再生的新型疗法
批准号:
8981311
负责人:
Alban P Gaultier
金额:
$35.31万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-15 至 2017-08-31

项目摘要

项目成果

Alban P Gaultier的其他基金

相似基金

相关文献

中文摘要
翻译
 描述(申请人提供):多发性硬化症(MS)是一种慢性且在很大程度上不可预测的中枢神经系统(CNS)疾病,其特征是针对包裹CNS神经元的髓鞘的自身免疫活动,导致病变部位的髓鞘细胞死亡,称为少突胶质细胞。由此导致的脱髓鞘,或髓鞘的退化,是这种疾病导致残疾和死亡的主要原因。目前已批准的治疗MS的方法旨在抑制免疫反应,但没有解决促进重新髓鞘形成的需要,而重新髓鞘形成是在MS病变形成后恢复功能缺陷所需的基本步骤。发展促进髓鞘再生和防止导致神经细胞死亡的不可逆转后果的治疗方法对于改善MS患者的生活质量和生存至关重要。中枢神经系统含有少突胶质前体细胞(OPC),有可能分化为成熟的少突胶质细胞,然后在MS攻击后能够对剥脱的轴突进行重新髓鞘形成。然而,残留在MS病变部位的髓鞘碎片通过需要激活小GTP酶Rho的过程抑制OPC向成熟少突胶质细胞的分化。缺乏功能成熟的少突胶质细胞,以及随后的重新髓鞘形成,加剧和延续了作为MS标志的功能缺陷。我们以前已经证明,低密度脂蛋白受体相关蛋白-1(LRP1)是中枢神经系统中髓鞘碎片的一种新受体。我们还在多种细胞类型和体内模型中显示,RAP显著减弱RhoA的激活。最近的研究表明,在MS啮齿动物模型中,OPC中LRP1的基因缺失促进了体内的再髓鞘形成,表明LRP1是一种新的髓鞘介导的OPC抑制分化的促进剂。LRP1缺失促进髓鞘生成的OPC分化的能力与LRP1拮抗剂RAP抑制RhoA活化的已知能力相结合,表明RAP是促进MS损伤后重新髓鞘形成的一种新的和令人兴奋的候选治疗方法。因此,RAP是一个重要的候选者,可以通过临床前概念验证测试,作为MS发作后恢复髓鞘形成和神经元功能的高价值潜在治疗方法。
英文摘要
 DESCRIPTION (provided by applicant): Multiple sclerosis (MS) is a chronic and largely unpredictable disease of the central nervous system (CNS) characterized by autoimmune activity against the myelin sheath encapsulating CNS neurons, which results in death of the myelinating cells, known as oligodendrocytes, within the lesion site. Resultant demyelination, or degradation of the myelin sheath, is the major contributor to the disability and death caused by this disease. Currently approved therapies for MS are aimed at inhibition of the immune response, but do not address the need to promote remyelination, which is the fundamental step needed to restore functional deficits after MS lesion formation. Development of therapeutics that promote remyelination and prevent irreversible consequences leading to neuronal cell death is paramount to improving the quality of life and survival of MS patients. The CNS contains oligodendrocyte precursor cells (OPCs) that have the potential to differentiate into mature oligodendrocytes, which would then be capable of remyelination of denuded axons after an MS attack. However, myelin debris lingering at MS lesion sites inhibits the differentiation of OPCs into mature oligodendrocytes through a process that requires that activation of the small-GTPase Rho. The lack of functional, mature oligodendrocytes, and subsequent remyelination, exacerbates and perpetuates functional deficits that are the hallmark of MS. We have previously demonstrated that the low-density lipoprotein receptor-related protein-1 (LRP1) is a novel receptor for myelin debris in the CNS. We have also shown in multiple cell types and in vivo models that RAP significantly attenuates activation of RhoA. More recent studies have demonstrated that genetic deletion of LRP1 in OPCs promotes remyelination in vivo, in rodent models of MS, indicating that LRP1 is a novel facilitator of myelin-mediated OPC suppression of differentiation. The ability of LRP1 deletion to enhance OPC differentiation of myelin production combined with the documented capacity of the LRP1 antagonist RAP to attenuate activation of RhoA indicate that RAP is a novel and exciting therapeutic candidate for enhancement of remyelination after MS lesion. As such, RAP is an important candidate to bring through pre-clinical proof-of-concept testing as a high-value potential therapeutic for restoring myelination and neuronal function after MS attack.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding the impact of Clusterin on the oligodendrocyte lineage in AD
  • 批准号:
    10539074
  • 项目类别:
  • 资助金额:
    $162.15万
  • 财政年份:
    2022
  • 负责人:
    Alban P Gaultier
  • 依托单位:
Discovering new therapies to promote myelin repair
  • 批准号:
    10314338
  • 项目类别:
  • 资助金额:
    $44.0万
  • 财政年份:
    2021
  • 负责人:
    Alban P Gaultier
  • 依托单位:
The role of oligodendrocyte progenitor cells in neuroinflammation
  • 批准号:
    10355928
  • 项目类别:
  • 资助金额:
    $46.27万
  • 财政年份:
    2021
  • 负责人:
    Alban P Gaultier
  • 依托单位:
NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS
  • 批准号:
    10011900
  • 项目类别:
  • 资助金额:
    $35.41万
  • 财政年份:
    2019
  • 负责人:
    Alban P Gaultier
  • 依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: